Clinical trials: Lipemia
Familial Hypercholesterolemia
Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal codominant single gene disorder caused by mutations in the LDL receptor gene (LDLR) that disrupt the normal clearance of LDL particles from the plasma.
- Trial name
- NCT02225340
- Where
- Canada
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Laval University
Hypercholesterolemia
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
- Trial name
- NCT03847974
- Testing
- LIB003
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- LIB Therapeutics LLC
HIV, Hypercholesterolaemia
Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels
To compare the effect of rosuvastatin to protease inhibitor switching on fasting total cholesterol over 12 weeks.
- Trial name
- SOS (NCT01935674)
- Testing
- Switch ritonavir-boosted PI, Continue Ritonavir-boosted PI+Rosuvastatin
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Juan A. Arnaiz
Hypercholesterolemia
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
- Trial name
- NCT00442897
- Testing
- simvastatin (+) ezetimibe, Comparator: atorvastatin
- Volunteers
- 229 people
- Sponsor
- Organon and Co
Hyperlipidemia
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein…
- Trial name
- RUTHERFORD-2 (NCT01763918)
- Testing
- Evolocumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Hypercholesterolemia
Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation
Background: It is becoming increasingly clear that individuals from all corners of the globe use probiotic dietary approaches to enhance health.
- Trial name
- NCT01341613
- Testing
- Cardioviva™ supplement capsule
- Where
- Czechia
- Volunteers
- 131 people
- Sponsor
- Micropharma Limited
Hyperlipidemia and Mixed Dyslipidemia
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
- Trial name
- OSLER-2 (NCT01854918)
- Testing
- Evolocumab, Standard of Care
- Where
- 363 sites in United States, Australia and 23 more
- Volunteers
- 3,681 people
- Sponsor
- Amgen
Hypercholesterolemia
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
This was a multicenter, non-randomized, non-interventional three-cohort study with prospective collection of primary data of treatment with newly initiated oral lipid lowering treatment on top of a statin (Oral LLT cohort), newly…
- Trial name
- NCT05362903
- Testing
- Inclisiran
- Where
- 121 sites in Germany
- Volunteers
- 1,868 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers
Type 2 diabetes mellitus (T2DM) is a chronic disorder determined by lifestyle and genes. It is associated with chronic hyperglycaemia along with other metabolic abnormalities.
- Trial name
- NCT01906359
- Testing
- Native palm olein (IV56), Chemically interesterified palm olein (IV56), High oleic sunflower oil
- Where
- 5 sites in Malaysia
- Volunteers
- 23 people
- Sponsor
- Malaysia Palm Oil Board
Hypercholesterolemia, Hyperlipidemias
Independent Effects of High-cholesterol (High-egg) and High-saturated Fat Diets on LDL-cholesterol
This study will comprise a randomized controlled, counter-balanced, cross-over trial to evaluate the independent effects of a high cholesterol (high egg), low saturated fat diet and a high saturated fat, low cholesterol diet on…
- Conditions
- Hypercholesterolemia, Hyperlipidemias, Physical Inactivity, Diet, Healthy
- Trial name
- NCT05267522
- Testing
- Egg diet, Egg-free Diet, Control Diet
- Where
- Australia
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- University of South Australia
Hypertriglyceridemia
A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules
Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3 medication comparator.
- Trial name
- PK/PD (NCT02310022)
- Testing
- Drug Omega 3, Drug Omega-3 Comparator
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Matinas Biopharma, Inc
Hyperlipidemia
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.
- Trial name
- NCT01133522
- Testing
- Evolocumab
- Volunteers
- 60 people
- Sponsor
- Amgen
Diabetes Mellitus, Arterial Hypertension
An Analysis of Diabetes Control in Puerto Rico
Project: An analysis of Diabetes Control in Puerto Rico Hypothesis: This project seeks to determine the causes for: i) poor adherence to prescribed treatment by patients, ii) low compliance by providers with national guidelines…
- Conditions
- Diabetes Mellitus, Arterial Hypertension, Hypercholesterolemia
- Trial name
- NCT01117831
- Testing
- Epidemiological intervention
- Volunteers
- 600 people
- Sponsor
- Center for Diabetes Control, Inc.
Obesity, Hypercholesterolemia
Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
This study aims to 1) assess the feasibility and acceptability of a prescribed beverage intervention in 50 obese Hispanic adults ages 18-64 years over 6 weeks; and 2) assess preliminary effects of the beverage intervention on…
- Conditions
- Obesity, Hypercholesterolemia, Hyperglycemia, Hypertriglyceridemia
- Trial name
- NCT02911753
- Testing
- Mediterranean Lemonade, Green Tea, Flavored Water
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells.
- Trial name
- NCT00025883
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Heterozygous Familial Hypercholesterolemia
Exploratory Study of Plaque Regression
Despite the availability of several classes of very effective drugs available to treat heterozygous Familial Hypercholesterolemia (HeFH), there remains a large unmet medical need for new, effective and well tolerated therapies.
- Trial name
- EXPRESS (NCT01515241)
- Testing
- CER-001
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Cerenis Therapeutics, SA
Hypercholesterolemia
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), to lower cholesterol in subjects with homozygous familial hypercholesterolemia undergoing lipid-lowering treatment.
- Trial name
- NCT00263081
- Testing
- Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 44 people
- Sponsor
- Takeda
ALK Fusion-positive Non-small Cell Lung Cancer
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
This prospective single-arm clinical study plans to enroll 29 participants with unresectable stage IIIB-IV ALK fusion-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07674368
- Testing
- Recaticimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hunan Cancer Hospital
Hyperlipidemia, Diabetes Mellitus, Type 2
Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus
The study will investigate the effects of atorvastatin on the concentrations of small, dense LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these effects.
- Conditions
- Hyperlipidemia, Diabetes Mellitus, Type 2, Non-Insulin Dependent Diabetes Mellitus
- Trial name
- ALPIN (NCT00640549)
- Testing
- Atorvastatin
- Where
- 14 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertriglyceridemia, Inflammation
Impacts of Lentils on Metabolism and Inflammation
The overall goal of this investigation is to determine gut microbiome dependent and independent impacts of pulse consumption on metabolic resilience and metabolic risk profiles for type 2 diabetes (T2D) and cardiovascular disease…
- Conditions
- Hypertriglyceridemia, Inflammation, Waist, Hypertriglyceridemic
- Trial name
- NCT04283448
- Testing
- Dietary Lentil, Control
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Montana State University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.